. 2021 Jan 30;2021:1250858. doi: 10.1155/2021/1250858

Table 1.

Effect of BGP-15 administration on gravimetric parameters of SHR animals.

	WKY (n = 7)	SHR-baseline (n = 7)	SHR-C (n = 7)	SHR-B (n = 7)
BW^START (g)	386.40 ± 4.33	343.21 ± 2.48^∗∗	346.90 ± 6.65^∗∗	340.73 ± 6.32^∗∗
BW^END (g)	401.45 ± 8.94	—	358.13 ± 5.08^∗∗	356.85 ± 4.54^∗∗
HW^END (g)	1.12 ± 0.04	1.16 ± 0.02	1.49 ± 0.05^∗∗^,##	1.23 ± 0.02^§§
VW^END (g)	0.95 ± 0.04	1.09 ± 0.02	1.33 ± 0.05^∗∗^,##	1.14 ± 0.02^§§
VW/BW^END (mg/g)	2.28 ± 0.11	3.19 ± 0.08^∗∗	3.73 ± 0.16^∗∗^,##	3.21 ± 0.03^∗^,§
VW/TL^END (mg/mm)	21.27 ± 0.79	24.76 ± 0.82^∗	29.79 ± 0.94^∗∗^,##	25.76 ± 0.46^∗^,§§
Lung wet weight/weight^END (g/g)	4.42 ± 0.26	4.51 ± 0.13	5.68 ± 0.24^∗∗^,##	4.68 ± 0.13^§§

BW^START: body weight at the beginning of the treatment; BW^END: body weight at the end of the treatment; HW^END: heart weight at the end of the treatment; VW^END: ventricles weight at the end of the treatment; TL^END: length of the right tibia at the end of the treatment. Values are means + SEM. WKY: age-matched normotensive Wistar-Kyoto rats, n = 7; SHR-Baseline: 15-month-old spontaneously hypertensive rats, n = 7; SHR-C: nontreated spontaneously hypertensive rats, n = 7; SHR-B: spontaneously hypertensive rats receiving BGP-15 for 18 weeks, n = 7. ^∗p < 0.05 vs. WKY, ^∗∗p < 0.01 vs. WKY, ^##p < 0.01 vs. SHR-Baseline, ^§p < 0.05 vs. SHR-C, ^§§p < 0.01 vs. SHR-C.